Effect of risperidone on S100B levels and relationship with treatment response in first-episode schizophrenic patients

Abstract

Abstract: AIM: To study if S100B levels is abnormity, to study the effect of risperidone on S100B levels and relationship between S100B levels and treatment response in first-episode schizophrenic patients. METHODS: Fifty-three first-episode schizophrenia inpatients according to DSM-IV were treated only with risperidone for 12 weeks, the Positive and Negative Syndrome Scale (PANSS), Clinical General Impression (CGI) and Hamiton Depression Rating Scale (HAMD) were estimated at the baseline and the endpoint to evaluate the clinical efficacy. The serum S100B levels of the patients at the baseline and the endpoint and the 58 healthy controls were assayed using Enzyme Linked Immunosorbent Assay (ELISA). RESULTS: The serum S100B levels of the patients groups were significantly higher than the controls (P<0.01) at the baseline, were significantly decreased after 12 weeks treatment with risperidone but remained significantly higher than controls (P<0.05). The serum S100B levels was negative correlated with the age of onset and score of HAMD(r= -0.28, -0.31, P all <0.05)at baseline, The serum S100B levels were significantly lower in the treatment responders comparing no-responders, were negative correlated with reduction of PANSS total score and negative subscore from baseline to 12 weeks (r=-0.28, -0.31, P all <0.05). CONCLUSION: The serum S100B levels of the schizophrenic patients are significantly higher than the healthy controls, Risperidone treatment reduced the S-100B levels that were associated with treatment response, indicating that patients with schizophrenia may suffer structural damage in central nervous system.

Key words: Schizophrenia, S100B, Risperidone, Treatment-response

CLC Number:

R749.3

LIU Lin-jing, XIU Mei-hong, ZHANG Xiang-yang, CHEN Da-chun. Effect of risperidone on S100B levels and relationship with treatment response in first-episode schizophrenic patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 313-317.

References

[1] Steiner J, Bernstein HG, Bielau H,et al. S100B immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study[J]. J Psychiatr Res, 2008, 42(10): 868-876.
[2] Liu Y, Buck DC, Neve KA. Novel interaction of the dopamine D2 receptor and the Ca²⁺ binding protein S100B: role in D2 receptor function[J]. Mol Pharmacol, 2008, 74(2): 371-378.
[3] Esposito G, De Filippis D, Cirillo C, et al. The astroglial-derived S100B eta protein stimulates the expression of nitric oxide synthase in rodent macrophages through p38 MAP kinase activation[J]. Life Sci, 2006, 78(23): 2707-2715.
[4] ZhangXY, Xiu MH, Song C, et al. Increased serum S100B in never-medicated and medicated schizophrenic patients [J]. J Psychiatr Res, 2010, 44(16): 1236-1240.
[5] 韩笑乐,谭云龙,杨甫德,等.首发未服药精神分裂症患者血清S100B蛋白浓度变化[J]. 中国神经精神疾病杂志, 2009, 35(11): 655-657.
[6] Qi LY, Xiu MH, Chen DC, et al. Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics[J]. Neurosci Lett, 2009, 462(2): 113-117.
[7] Steiner J, Walter M, Wunderlich MT, et al. A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE[J]. Biol Psychiatry, 2009, 65(12): 1107- 1110.
[8] Tramontina F, Tramontina AC, Souza DF, et al. Glutamate uptake is stimulated by extracellular S100B in hippocampal astrocytes [J]. Cell Mol Neurobiol, 2006, 26(1): 81-86.
[9] Buttner T, Weyers S, Postert T, et al. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction[J]. Stroke, 1997, 28 (10): 1961-1965.
[10] Van Eldik LJ, Griffin WS. S100 beta expression in Alzheimer's disease: relation to neuropathology in brain regions [J]. Biochim Biophys Acta, 1994, 1223(3): 398-403.
[11] Asli S, Selcuk K, Cengiz AK, et al. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: Effects of short term antipsychotic treatment[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31(6): 1164-1169.
[12] Steiner J, Bernstein HG, Bogerts B, et al. Haloperidol and clozapine decrease S100B release from glial cells [J]. Neuroscience, 2010, 167(4): 1025-1031.
[13] Ling S H, Tang YL, Jiang F, et al. Plasma S-100B protein in Chinese patients with schizophrenia: Comparison with healthy controls and effect of antipsychotics treatment[J]. J Psychiatric Res, 2007, 41(1/2): 36- 42.
[14] Rothermundt M, Ponath G, Glaser T, et al. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia[J]. Neuropsychopharmacology, 2004, 29(5): 1004- 1011.
[15] Rothermundt M, Missler U, Arolt V, et al. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology[J]. Mol Psychiatry, 2001, 6(4): 445-449.